They identified a DC gene signature based on the ratio of CD103+/CD103−, associated genes that provide a strong pro-immune survival signal in different cancer, including head-neck squamous cell carcinoma, suggesting that CD103+ cDC1s are critical for robust tumor control in both mice and humans [128]. The gene discussed is ITGAE; the disease is cancer.